[go: up one dir, main page]

TW200505834A - Sulfamide derivative and the pharmaceutical composition thereof - Google Patents

Sulfamide derivative and the pharmaceutical composition thereof

Info

Publication number
TW200505834A
TW200505834A TW093107069A TW93107069A TW200505834A TW 200505834 A TW200505834 A TW 200505834A TW 093107069 A TW093107069 A TW 093107069A TW 93107069 A TW93107069 A TW 93107069A TW 200505834 A TW200505834 A TW 200505834A
Authority
TW
Taiwan
Prior art keywords
fomula
pharmaceutical composition
sulfamide derivative
pharmaceutically acceptable
acceptable salts
Prior art date
Application number
TW093107069A
Other languages
Chinese (zh)
Inventor
Tomoyuki Shibata
Masaki Kiga
Hayato Iwadare
Naomi Shimazaki
Tomoki Echigo
Kosaku Fujiwara
Fumie Tanzawa
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of TW200505834A publication Critical patent/TW200505834A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides a sulfamide derivative of the following fomula(I) and the pharmaceutically acceptable salts, and provides a pharmaceutical composition, which is administrated separatly in same time or with interval sulfamide derivative of the following fomula(I) and the pharmaceutically acceptable salts, and a compound of the fomula(IV) and the pharmaceutically acceptable salts etc. , (in fomula(I), R1~R8 is a hydrogen atom or a halogen atom etc., R9 or R10 is a hydrogen atom, an optionally substituted alkyl group etc.), and in fomula(IV), X is a benzoimidazolyl group, Y1 is an oxygen atom etc. Z is a 2,4-dioxothiazoridin-5-yl group etc., R is a hydrogen atom, C1-6 alkyl group etc., m is an integer of 1~5).
TW093107069A 2003-03-18 2004-03-17 Sulfamide derivative and the pharmaceutical composition thereof TW200505834A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003073615 2003-03-18
JP2003112572 2003-04-17
JP2003379282 2003-11-10

Publications (1)

Publication Number Publication Date
TW200505834A true TW200505834A (en) 2005-02-16

Family

ID=33033079

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093107069A TW200505834A (en) 2003-03-18 2004-03-17 Sulfamide derivative and the pharmaceutical composition thereof

Country Status (2)

Country Link
TW (1) TW200505834A (en)
WO (1) WO2004083167A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
ES2308127T3 (en) * 2004-10-22 2008-12-01 Bioprojet NEW DERIVATIVES OF DICARBOXYL ACIDS.
GB0513702D0 (en) 2005-07-04 2005-08-10 Sterix Ltd Compound
CN101495118B (en) * 2005-07-21 2012-09-05 阿迪亚生命科学公司 N-(Arylamino)sulfonamide Inhibitors of MEK
US8101799B2 (en) 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
CA2618218C (en) 2005-07-21 2015-06-30 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of mek
SI1934174T1 (en) 2005-10-07 2011-08-31 Exelixis Inc Azetidines as mek inhibitors for the treatment of proliferative diseases
BRPI0707671A2 (en) 2006-02-09 2011-05-10 Daiichi Sankyo Co Ltd anti-cancer pharmaceutical composition
WO2007110449A1 (en) 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
US7842836B2 (en) * 2006-04-11 2010-11-30 Ardea Biosciences N-aryl-N'alkyl sulfamides as MEK inhibitors
TW200812963A (en) 2006-04-13 2008-03-16 Euro Celtique Sa Benzenesulfonamide compounds and the use thereof
WO2007118853A1 (en) 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and their use as blockers of calcium channels
TR201900306T4 (en) 2006-12-14 2019-02-21 Exelixis Inc Methods of using Mek inhibitors.
ES2547303T3 (en) * 2007-01-19 2015-10-05 Ardea Biosciences, Inc. MEK inhibitors
TW201336497A (en) * 2007-02-08 2013-09-16 Daiichi Sankyo Co Ltd Crystal form of thiazolidinedione compound and preparation method thereof
WO2008124118A1 (en) 2007-04-09 2008-10-16 Purdue Pharma L.P. Benzenesulfonyl compounds and the use therof
WO2008150470A1 (en) 2007-05-31 2008-12-11 Shionogi & Co., Ltd. Oxyimino compounds and the use thereof
US8765736B2 (en) 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
ES2408159T3 (en) 2008-06-11 2013-06-18 Shionogi & Co., Ltd. Oxycarbamoyl compounds and their use
WO2010013769A1 (en) 2008-07-31 2010-02-04 第一三共株式会社 Crystal of thiazolidinedione compound, and process for production thereof
US20110124692A1 (en) 2008-07-31 2011-05-26 Daiichi Sankyo Company, Limited Crystalline forms of thiazolidinedione compound and its manufacturing method
JP5746630B2 (en) 2008-11-10 2015-07-08 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ Substituted sulfonamidophenoxybenzamide
JP2013508320A (en) * 2009-10-21 2013-03-07 バイエル・ファルマ・アクチェンゲゼルシャフト Substituted halophenoxybenzamide derivatives
US8962606B2 (en) 2009-10-21 2015-02-24 Bayer Intellectual Property Gmbh Substituted benzosulphonamides
US20120269803A1 (en) 2009-10-21 2012-10-25 Bayer Intellectual Property Gmbh Substituted benzosulphonamides
CA2816188A1 (en) 2010-10-29 2012-05-03 Marion Hitchcock Substituted phenoxypyridines
EP2854779A1 (en) 2012-05-31 2015-04-08 Bayer Pharma Aktiengesellschaft Biomarkers for determining effective response of treatments of hepatocellular carcinoma (hcc) patients
BR112015008113B1 (en) 2012-10-12 2022-05-24 Exelixis, Inc. New process to prepare compounds for use in cancer treatment
ES2703208T3 (en) * 2013-02-27 2019-03-07 Daiichi Sankyo Co Ltd Method for predicting sensitivity to a compound that inhibits the MAPK signal transduction pathway
EP4086250B1 (en) 2016-07-06 2024-12-11 The Regents Of The University Of Michigan Multifunctional inhibitors of mek/pi3k and mtor/mek/pi3k biological pathways and therapeutic methods using the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567831A (en) * 1995-08-16 1996-10-22 Duguesne University Of The Holy Ghost Non-steroidal sulfatase inhibitor compounds and their method of use
JP4320089B2 (en) * 1999-07-06 2009-08-26 あすか製薬株式会社 Phenylsulfamate derivatives
JP2002020362A (en) * 2000-07-06 2002-01-23 Nippon Oruganon Kk New biphenyl derivative

Also Published As

Publication number Publication date
WO2004083167A1 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
TW200505834A (en) Sulfamide derivative and the pharmaceutical composition thereof
GEP20115347B (en) Heterocyclocarboxamide derivatives
NZ536734A (en) Spiroindolinepiperidine derivatives
HUP0303756A2 (en) 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands and process for their preparation and pharmaceutical compositions containing them
AP1614A (en) New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents.
ATE388958T1 (en) 4'-C-SUBSTITUTED 2-HALOADENOSINE DERIVATIVES
JO2354B1 (en) Novel aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
NO20051389L (en) Stabilized pharmaceutical composition containing basic aids
MX2009006334A (en) Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives.
WO2004000817A3 (en) Benzimidazole compounds and their use as estrogen agonists/antagonists
WO2001014330A3 (en) Phenylpiperazines as serotonin reuptake inhibitors
NO20045486L (en) New compounds and their use
PH12015501098A1 (en) Antituberculous composition comprising oxazole compounds
TW200745034A (en) New compounds
TW200724136A (en) Pharmaceutical compositions comprising PPAR modulator
GEP20084300B (en) 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists
YU56402A (en) 8,8a-dihydro-indeno/1,2-d/thiazole derivatives with sulphonamido or sulphono substituent in the 2 position, a method for production thereof and use thereof as medicament
JO2413B1 (en) Benzoxazine Derivatives And Uses Thereof
MXPA05013631A (en) Heterocyclic methyl sulfone derivative.
TW200606152A (en) Piperidine compound and process for preparing the same
NO20052074L (en) Substituted benzoxazinones and uses thereof.
MY140749A (en) Novel piperidine compound
NO20054135L (en) Kipolinone / benzoxazine derivatives and uses thereof
NO20062491L (en) Benzoxazine derivatives and their use
AU2001269540A1 (en) Serotonin reuptake inhibitors